Cargando…

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis

Detalles Bibliográficos
Autores principales:	Alexeeva, E, Denisova, R, Valieva, S, Bzarova, T, Isayeva, K, Sleptsova, T, Mitenko, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194561/ http://dx.doi.org/10.1186/1546-0096-9-S1-P202

Ejemplares similares

Early treatment with infliximab in patients with juvenile idiopathic arthritis
por: Sleptsova, TV, et al.
Publicado: (2011)

PReS-FINAL-2041: Macrophage activation syndrome in the children with systemic juvenile idiopathic arthritis during the course of tocilizumab
por: Alekseeva, E, et al.
Publicado: (2013)

Effects of antirheumatic treatment with tocilizumab on longitudinal growth in children with juvenile idiopathic arthritis
por: Alexeeva, Ekaterina, et al.
Publicado: (2014)

Quality of life in patients with juvenile arthritis: adalimumab might make a difference
por: Denisova, Rina, et al.
Publicado: (2011)

Juvenile idiopathic arthritis is a diagnosis of exclusion
por: Alexeeva, Ekaterina, et al.
Publicado: (2014)

P02-029 - CAPS or SJIA
por: Alekseeva, E, et al.
Publicado: (2013)

P02-011 - TRAPS syndrome debuted as systemic JIA
por: Sleptsova, T, et al.
Publicado: (2013)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
por: Nemiche, O, et al.
Publicado: (2011)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

The use of tocilizumab in a child with systemic onset juvenile idiopathic arthritis and ganglioneuroblastoma
por: Goran, Ristic, et al.
Publicado: (2011)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
por: Katargina, LA, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
por: De Benedetti, F, et al.
Publicado: (2011)

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
por: De Benedetti, Fabrizio, et al.
Publicado: (2014)

Tocilizumab therapy in systemic juvenile idiopathic arthritis – lessons of real clinical practice
por: Kaleda, Maria I, et al.
Publicado: (2014)

Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia
por: Alexeeva, Ekaterina I., et al.
Publicado: (2017)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
por: Yokota, S, et al.
Publicado: (2008)

Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA)
por: Verazza, S, et al.
Publicado: (2008)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
por: Yamaguchi, Ken-ichi, et al.
Publicado: (2012)

PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy
por: Sato, T, et al.
Publicado: (2013)

MEFV mutations in Iranian children with systemic onset juvenile idiopathic arthritis
por: Farivar, Shirin, et al.
Publicado: (2014)

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
por: Deslypere, G, et al.
Publicado: (2011)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

Thalidomide: efficacy and side effects in juvenile idiopathic arthritis (JIA)
por: Alpigiani, MG, et al.
Publicado: (2008)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Efficacy of oral versus subcutaneous methotrexate in children with juvenile idiopathic arthritis
por: Tzaribachev, N, et al.
Publicado: (2008)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

Temporomandibular joint involvement in children with juvenile idiopathic arthritis
por: Cannizzaro, E, et al.
Publicado: (2008)

Phenotypes of juvenile idiopathic arthritis
por: Rokhlina, Faina, et al.
Publicado: (2014)

IL-6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis
por: Yokota, S, et al.
Publicado: (2003)

Anakinra treatment in patients with systemic-onset juvenil idiopathic arthritis: “The Valencia Experience”
por: Marvillet, I, et al.
Publicado: (2011)

PReS-FINAL-2060: The role of stress factors in the onset of juvenile idiopathic arthritis
por: Stepanenko, N, et al.
Publicado: (2013)

PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan
por: Yokota, S, et al.
Publicado: (2013)

Turkish Pediatric Rheumatology Society consensus statements on systemic onset juvenile idiopathic arthritis in Turkey
por: Sozeri, B, et al.
Publicado: (2015)

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
por: De Benedetti, F, et al.
Publicado: (2013)

Illness representation in adolescents with juvenile idiopathic arthritis
por: Lelieveld, OTHM, et al.
Publicado: (2008)

Ocular threat in juvenile idiopathic arthritis (JIA)
por: Marvillet, I, et al.
Publicado: (2008)

Macrophage activation sydrome with systemic onset juvenile idiopathic arthritis (SOJIA) in Chinese childern
por: Li, C, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_csdtl5h14fgaurd84kl3q6t71v